drugset
drugset / Trial / NCT06598384

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML

NCT06598384 ↗

Phase 2 Not yet recruiting 40 enrolled Navy General Hospital, Beijing
NaSingle-groupOpen-labelTreatment

Summary

The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Timeline

Start
2024-09
Primary completion
2030-09
Completion
2030-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacytidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Venetoclax Small molecule 400 mg Oral

Indications

acute myeloid leukemia